[go: up one dir, main page]

AU2004246849A1 - Treatment for alzheimer's disease and related conditions - Google Patents

Treatment for alzheimer's disease and related conditions Download PDF

Info

Publication number
AU2004246849A1
AU2004246849A1 AU2004246849A AU2004246849A AU2004246849A1 AU 2004246849 A1 AU2004246849 A1 AU 2004246849A1 AU 2004246849 A AU2004246849 A AU 2004246849A AU 2004246849 A AU2004246849 A AU 2004246849A AU 2004246849 A1 AU2004246849 A1 AU 2004246849A1
Authority
AU
Australia
Prior art keywords
compounds
inhibit
secretion
disease
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004246849A
Other languages
English (en)
Inventor
Jose Luis Castro Pineiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of AU2004246849A1 publication Critical patent/AU2004246849A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004246849A 2003-06-13 2004-06-04 Treatment for alzheimer's disease and related conditions Abandoned AU2004246849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0313772.6A GB0313772D0 (en) 2003-06-13 2003-06-13 Therapeutic treatment
GB0313772.6 2003-06-13
PCT/GB2004/002381 WO2004110443A1 (fr) 2003-06-13 2004-06-04 Traitement de la maladie d'alzheimer et de pathologies associees

Publications (1)

Publication Number Publication Date
AU2004246849A1 true AU2004246849A1 (en) 2004-12-23

Family

ID=27636512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004246849A Abandoned AU2004246849A1 (en) 2003-06-13 2004-06-04 Treatment for alzheimer's disease and related conditions

Country Status (8)

Country Link
US (1) US20060121034A1 (fr)
EP (1) EP1638563A1 (fr)
JP (1) JP2006527244A (fr)
CN (1) CN1805746A (fr)
AU (1) AU2004246849A1 (fr)
CA (1) CA2528395A1 (fr)
GB (1) GB0313772D0 (fr)
WO (1) WO2004110443A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2009128057A2 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
EA201171143A1 (ru) * 2009-03-19 2012-03-30 Бристол-Маерс Сквибб Компани Новое соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продукции бета амилоидного пептида
EP2533780B1 (fr) 2010-02-12 2017-08-23 AskAt Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ151495A3 (en) * 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
EA199800337A1 (ru) * 1995-10-27 1998-10-29 Мерк Энд Ко., Инк. Способ получения гормона роста, усиливающего секрецию
JP2002015538A (ja) * 2000-06-30 2002-01-18 Sony Corp テープカセット
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
HRP20040075B1 (en) * 2001-08-21 2012-03-31 Merck Sharp & Dohme Limited Novel cyclohexyl sulphones
MXPA05009850A (es) * 2003-03-14 2005-12-06 Merck Sharp & Dohme Metodo para tratar el deterioro cognitivo leve y para prevenir o atrasar la enfermedad de alzheimer.

Also Published As

Publication number Publication date
CN1805746A (zh) 2006-07-19
JP2006527244A (ja) 2006-11-30
GB0313772D0 (en) 2003-07-23
EP1638563A1 (fr) 2006-03-29
WO2004110443A1 (fr) 2004-12-23
US20060121034A1 (en) 2006-06-08
CA2528395A1 (fr) 2004-12-23

Similar Documents

Publication Publication Date Title
ES2275654T5 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
CN100348189C (zh) DPP－IV抑制剂与PPAR－α化合物的组合
CN102834099B (zh) Dgat1抑制剂的用途
JP2006512417A5 (fr)
US7834056B2 (en) Pharmaceutical composition for gout
KR101909433B1 (ko) 키나제 저해제의 부작용 저감제
US20060241133A1 (en) Electrically variable pneumatic structural element
BR112020001074A2 (pt) composição
JP2010065060A (ja) 心不全処置のための複合治療
AU2004246849A1 (en) Treatment for alzheimer's disease and related conditions
US20080051403A1 (en) Treatment For Alzheimer's Disease And Related Conditions
US20060183764A1 (en) Combination of gh secret agogues and pde4 inhibitors for the treatment of alzheimers disease
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
ES2281775T3 (es) Metodo para tratar insuficiencia renal.
KR101016927B1 (ko) 알츠하이머 질환의 치료용 ｎｍｄａ 길항제 및 아세틸콜린에스테라제 억제제의 조합물
JP2008501656A (ja) β−アミロイド（Ａβ４０及びＡβ４２）生成阻害のためのモノアミン神経伝達物質再取り込み阻害剤
CN117083055A (zh) 用于治疗神经退行性认知障碍的胆碱酯酶抑制剂和季铵抗毒蕈碱剂的固定剂量组合
CA2213507A1 (fr) Composition pharmaceutique pour le traitement des accidents ischemiques transitoires
HK40005150B (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
TW201924677A (zh) 苯并咪唑衍生物用於夜間酸突破的用途
JP2009084253A (ja) 頭痛の予防および／または治療剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period